RHGH 36 IU Nouveaux LTD

RHGH 36 IU/cartige

Nouveaux Recombinant Human Growth Hormone – rDNA origin is human growth hormone produced by identical to the dominant form of this human pituitary growth hormone. It has a molecular weight of 22,125 daltons.

Nouveaux rHGH is a sterile, non-pyrogenic, white lyophilised powder intended for subcutaneous or intramuscular injection, after reconstitution with sterile Water for Injection (0,3% m-Cresol).

+ Mechanism of action

Somatropin (as well as endogenous HGH) binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by IGF-I produced in the liver and also locally (e.g., skeletal growth, protein synthesis), while others are primarily a consequence of the direct effects of somatropin (e.g., lipolysis).

• Tissue Growth
• Skeletal Growth
• Cell Growth
• Organ Growth
• Protein Metabolism
• Carbohydrate Metabolism
• Lipid Metabolism
• Mineral Metabolism
• Connective Tissue Metabolism

+ Adverse reaction

The list presents the most serious and/or most frequently observed adverse reactions during treatment with somatropin:

• Sudden death in paediatric patients with Prader-Willi syndrome with risk factors including severe obesity, history of upper airway obstruction or sleep apnea and unidentified respiratory infection.
• Intracranial tumours, in particular meningiomas, in teenagers/young adults treated with radiation to the head as children for a first neoplasm and somatropin.
• Glucose intolerance including impaired glucose tolerance/impaired fasting glucose as well as overt diabetes mellitus.
• Intracranial hypertension.
• Significant diabetic retinopathy.
• Slipped capital femoral epiphysis in paediatric patients.
• Progression of preexisting scoliosis in paediatric patiens.
• Fluid retention manifested by edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paraesthesias.
• Unmasking of latent central hypothyroidism.
• Injection site reactions/rashes and lipoatrophy (as well as rare generalized hypersensitivity reactions).
• Pancreatitis.

+ Instructions for reconstitution

The injection is given into the sub-cutaneous layer which includes adipose tissue (fat).

If you are using insulin syringes which have short needles, you will need to enter the skin at 90°. to the skin, otherwise you can inject as shown in the illustration above with a 29 or 30 gauge, 0.5″ needle.

+ Dosage

Recommended dosage of rHGH: 2-4 IU once per day.

+ Storage

• This product can be used not more than 3 years from the production date (see box).
• After reconstitution, may be stored for a maximum of 14 days in a refrigerator at 2°C – 8°C.
• Store vials in an upright position.
• Store in a refrigerator (2°C – 8°C). Keep in the outer carton in order to protect from light.
• For one month can be stored at room temperature.